Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPAS1 | Q99814 | 14/20 | 0.49 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131292 | 0.89 | MEN1 (0.51) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL5083041 | 0.80 | MEN1 (0.58) | ENPP2KMT2AMEN1 | |
| SCHEMBL197216 | 0.78 | ALDH1A1 (0.52) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL4126727 | 0.78 | ALDH1A1 (0.52) | KMT2AMEN1 | |
| SCHEMBL30512217 | 0.78 | EPAS1 (0.44) | EPAS1VEGFA | |
| SCHEMBL22558454 | 0.77 | AKR1C3 (0.55) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL9870770 | 0.77 | TDP1 (0.68) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL12584886 | 0.77 | TDP1 (0.68) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL4126119 | 0.77 | AKR1C3 (0.55) | ENPP3ENPP1ENPP2KMT2AMEN1 | |
| SCHEMBL30793395 | 0.77 | MEN1 (0.65) | ENPP3ENPP1ENPP2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487109-B2 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI (FR) | 2013-07-16 | — | — | US | disclosed |
| EP-2176203-B1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI SA (FR) | 2011-08-10 | — | — | EP | disclosed |
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | SANOFI-AVENTIS (FR) | 2010-10-14 | — | — | US | disclosed |
| EP-2176203-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| CN-101687734-A | The coupled reaction method of catalytic terminal alkynes class of palladium and aryl tosylate class | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| WO-2009003589-A1 | A PROCESS FOR THE PALLADIUM-CATALYZED COUPLING OF TERMINAL ALKYNES WITH ARYL TOSYLATES | SANOFI-AVENTIS (FR) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261910-A1 | Process for the palladium-catalyzed coupling of terminal alkynes with aryl tosylates | TYR, ALK, TYRO3 | EPAS1 2776/4885ENPP3 1010/4885ENPP1 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.